Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Terminated 2

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Lymphoid 2

Conditions

Carcinoma, Non-Small-Cell Lung 3Recurrence 2Myelodysplastic Syndromes 2Lymphoma, Large B-Cell, Diffuse 2Leukemia, Myeloid, Acute 2Hodgkin Disease 2Stomach Neoplasms 1Prostatic Neoplasms 1Neoplasm Metastasis 1Lymphoma, Non-Hodgkin 1Lymphoma, Mantle-Cell 1Lymphoma, Follicular 1Lymphoma 1Lung Neoplasms 1Leukemia 1Breast Neoplasms 1

Interventions

Rituximab 67Cyclophosphamide 41fludarabine phosphate 17Etoposide 17Doxorubicin 17Vincristine 16Prednisone 16Filgrastim 14Mycophenolic Acid 13Cyclosporine 13Lenalidomide 12Antilymphocyte Serum 12Gemcitabine 11Radiotherapy 10fludarabine 9Peripheral Blood Stem Cell Transplantation 9Methotrexate 9Whole-Body Irradiation 8Tacrolimus 8Melphalan 8Carboplatin 8Bortezomib 8venetoclax 7Dexamethasone 7Cord Blood Stem Cell Transplantation 7Busulfan 7ibritumomab tiuxetan 6Ifosfamide 6Flow Cytometry 6obinutuzumab 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Terminated × Lymphoma, Large B-Cell, Diffuse × mocetinostat × Clear all
NCT02282358 2024-03-08

Study of Mocetinostat in Selected Patients With Mutations of Acetyltransferase Genes in Relapsed and Refractory Diffuse Large B-Cell Lymphoma and Follicular Lymphoma

Memorial Sloan Kettering Cancer Center

Phase 1/2 Terminated
7 enrolled 11 charts
Lymphoid

Lymphoma, Lymphoma, Follicular, Recurrence, Lymphoma, Large B-Cell, Diffuse

NCT00543582 2015-07-01

MGCD0103 Administered in Combination With Azacitidine (Vidaza®) to Subjects With Relapsed or Refractory Hodgkin or Non-Hodgkin Lymphoma

Mirati Therapeutics Inc.

Phase 2 Terminated
23 enrolled
Lymphoid

Hodgkin Disease, Lymphoma, Non-Hodgkin, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Mantle-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡